Nomogram developed to estimate early breast cancer survival

Nomogram developed to estimate early breast cancer survival
A nomogram has been developed to predict five- and 10-year mastectomy-free survival in older women with early breast cancer and estimate the predicted benefit of radiation therapy following conservative surgery, according to research published online June 25 in the Journal of Clinical Oncology.

(HealthDay) -- A nomogram has been developed to predict five- and 10-year mastectomy-free survival (MFS) in older women with early breast cancer and estimate the predicted benefit of radiation therapy (RT) following conservative surgery (CS), according to research published online June 25 in the Journal of Clinical Oncology.

In an effort to develop a to predict five- and 10-year MFS rates with and without RT, Jeffrey M. Albert, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues utilized population-based data from 16,092 women aged 66 to 79 years who participated in the Surveillance, Epidemiology and End Results Program.

The researchers found that overall five- and 10-year MFS rates were 98.1 and 95.4 percent, respectively, after a median follow-up period of 7.2 years. Significant predictors of time to mastectomy included age, race, , estrogen receptor status, receipt of radiotherapy, and nodal status. The nomogram developed was able to accurately predict MFS.

"In summary, we used population-based data to develop a nomogram to estimate five- and 10-year MFS among older women with early treated with CS," the authors write. "This clinically useful tool uses readily available clinicopathologic factors to estimate the probability of MFS and can further aid individualized clinical decision making by estimating the potential benefit from RT for this large and growing patient population."

One study author disclosed a financial tie to Varian Medical Systems, which contributed funding to the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Blood biomarker may detect lung cancer

8 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

Oct 20, 2014

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments